RECOMBINANT PLASMID PFM-IFN-17 PROVIDING EXPRESSION OF INTERFERON ALPHA-2B OF HUMAN, RECOMBINANT PLASMID PFM-AP, PROVIDING EXPRESSION OF ENZYME METHIONINE-AMINOPEPTIDASE E COLI, BIPLASMID STRAIN ESCHERICHIA COLI FM-IFN-AP (PFM-IFN-17, PFM-AP) - PRODUCER (MET-) OF RECOMBINANT INTERFERON ALPHA -2B OF HUMAN Russian patent published in 2017 - IPC C12N15/21 C12N15/63 C12N1/21 C12N15/09 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the biotechnologies. The invention represents the recombinant strain of bacteria E. coli FM-IFN, which is produced by means of the successive transformation of the strain cells E. coli BL21 by recombinant plasmid DNA pFM-AP and pFM-IFN-17, recombinant plasmid DNA pFM-AP with the size of 4,582 b.p., which encodes the inducible synthesis of the enzyme methionine-aminopeptidase E.coli under the control of a lactose promoter and contains the gene cm, which determines the resistances to chloramphenicol, as a genetic marker, recombinant plasmid DNA pFM-IFN-17 with the size of 3,215 b.p., which encodes the synthesis of the interferon alpha-2b of a human under the control the lactose and tryptophanic promotor and terminator of the transcription rrnBT1T2 and contains the synthetic gene km, which determines the resistances to kanamycin, as a genetic marker.

EFFECT: production of recombinant interferon aplpha-2b of a human free from methionine on the N-end with the high output and following the simplified technology.

4 cl, 8 dwg, 1 tbl, 6 ex